Citizens JMP raised the firm’s price target on Benitec Biopharma (BNTC) to $22 from $20 and keeps an Outperform rating on the shares. Benitec presented a 100% response rate for the BB-301 Phase 1b/2a study at the low dose and debuted a composite primary endpoint that sets an easily achievable bar for FDA approval, the analyst tells investors in a research note. The firm continues to be encouraged by the efficacy of BB-301 with several measures showing improvements as the patient number grows to six from three.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTC:
- Benitec Biopharma’s BB-301 Receives FDA Fast Track
- Benitec provide interim clinical results for BB-301 Phase 1b/2a trial of BB-301
- Benitec Biopharma appoints Mates to board of directors
- Benitec Biopharma’s BB-301 Study: A Potential Game-Changer for OPMD Treatment?
- Benitec Biopharma’s Strong Financial Position and Promising Clinical Progress Justify Buy Rating